Sign up to save your podcasts
Or
Share GeoVax Labs Reports Year-End Results and Key Accomplishments
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
GeoVax Labs Reports Year-End Results and Key Accomplishments
GeoVax Labs, Inc. shares its financial results for 2024 and provides updates on ongoing trials and clinical evaluations of its vaccine candidates. The company is preparing for Phase 2b trial of GEO-CM04S1, conducting clinical evaluations of GEO-MVA, and planning a Phase 2 trial of Gedeptin(R) for head and neck cancer treatment. Additionally, GeoVax will host a conference call to discuss these updates and financial results.
View all episodes
GeoVax Labs, Inc. shares its financial results for 2024 and provides updates on ongoing trials and clinical evaluations of its vaccine candidates. The company is preparing for Phase 2b trial of GEO-CM04S1, conducting clinical evaluations of GEO-MVA, and planning a Phase 2 trial of Gedeptin(R) for head and neck cancer treatment. Additionally, GeoVax will host a conference call to discuss these updates and financial results.